COGNITION THERAPEUTICS INC

Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced it will host a conference call and webcast on November 5, 2026, at 8:30 a.m. Eastern Time. The call will cover the company's financial results for the third quarter ended September 30, 2026, and provide a business update. Details for accessing the call and webcast have been provided.

COGNITION THERAPEUTICS INC reported a net loss of $3.93 million for the second quarter of 2026, an improvement from a $6.73 million loss in the same period last year. For the first half of 2026, the net loss was $8.50 million, down from $15.21 million in the prior year. The company's cash and cash equivalents stood at $34.01 million as of June 30, 2026, and it believes these funds are sufficient to support operations for at least one year. The company also raised $6.95 million through its 2025 At-The-Market (ATM) program during the first six months of 2026.

Cognition Therapeutics reported a reduced net loss of $(3.9) million for the second quarter of 2026, an improvement from $(6.7) million in the prior year. The company also announced significant progress in its clinical and corporate priorities, including a patent allowance for zervimesine that extends intellectual property protection through 2045. Discussions with the FDA for a planned Phase 3 trial in DLB psychosis are ongoing, with an aim to initiate the study in mid-2027.

Cognition Therapeutics, Inc. announced that its President and CEO, Lisa Ricciardi, will participate in a fireside discussion at the B. Riley Mind, Muscle & Vision Summit on July 16, 2026. During the event, Ms. Ricciardi will provide updates on the company's ongoing START study and discuss the planned initiation of a Phase 3 registrational study for zervimesine (CT1812) in dementia with Lewy bodies (DLB) psychosis. Zervimesine is an investigational once-daily oral therapy that has shown promise in Phase 2 trials.

Cognition Therapeutics announced it received written feedback from the U.S. Food and Drug Administration (FDA) following a recent meeting. The FDA agreed that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome and aligned with the company on key aspects of a pivotal trial for Zervimesine (CT1812). The registrational program is expected to commence in mid-2027, with the company developing the Neuropsychiatric Inventory (NPI) as a novel primary endpoint for DLB psychosis.

Cognition Therapeutics announced it received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its lead product candidate, zervimesine. The FDA agreed that psychosis associated with dementia with Lewy bodies (DLB) could be an approvable outcome and aligned with the company on key aspects of a pivotal trial design. The registrational program is expected to commence in mid-2027, with a Phase 3 study enrolling DLB patients experiencing psychosis symptoms. This development follows promising Phase 2 results where zervimesine slowed the progression of hallucinations and delusions by 89%.

Cognition Therapeutics announced it received a Notice of Allowance from the USPTO for a patent covering a polymorphic crystalline form of zervimesine (CT1812), its lead drug candidate. This patent, once issued, will protect the key formulation through 2045, with a potential extension to 2050. The new form offers enhanced stability and will be used in upcoming registrational trials for dementia with Lewy bodies (DLB) psychosis.

Cognition Therapeutics presented an investor update highlighting the advancement of its lead asset, zervimesine (CT1812), towards a registrational trial for Dementia with Lewy bodies (DLB) psychosis. The company reported strong Phase 2 SHIMMER study results, showing an 86% slowing of NPI-12 decline in neuropsychiatric symptoms versus placebo. With $31.2 million in cash and equivalents and $25.6 million in remaining grant funds as of March 31, 2026, the company has a cash runway into Q2 2027. Additionally, the START Phase 2 trial for early Alzheimer's, fully funded by an $81 million NIA grant, is ongoing with data expected in 2H 2027.

Cognition Therapeutics, Inc. announced that its President and CEO, Lisa Ricciardi, will present at the 2026 Jefferies Global Healthcare Conference and the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit in June. Ms. Ricciardi will provide updates on the company's plans for a registration program in dementia with Lewy bodies (DLB) psychosis. The company's lead candidate, zervimesine (CT1812), is an investigational oral therapy that has shown promise in Phase 2 clinical trials for DLB and mild-to-moderate Alzheimer's disease.

Cognition Therapeutics announced the completion of a productive meeting with the U.S. Food and Drug Administration (FDA) regarding its drug candidate, zervimesine (CT1812), for dementia with Lewy bodies (DLB) patients with psychosis. The discussions focused on the results from the Phase 2 SHIMMER study and the proposed plan to advance zervimesine into a registrational program. The company believes it has a clear path forward for the drug's development and anticipates reviewing the FDA's formal minutes in June.